Research programme: acute pain therapeutics - New River Pharmaceuticals

Drug Profile

Research programme: acute pain therapeutics - New River Pharmaceuticals

Latest Information Update: 10 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New River Pharmaceuticals
  • Class Morphine derivatives
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute pain

Most Recent Events

  • 21 Feb 2008 Discontinued - Preclinical for Acute pain in USA (PO)
  • 12 Aug 2005 New River Pharmaceuticals initiates clinical trials of NRP 290 for acute pain in the USA
  • 28 Jun 2005 New River files an IND application for NRP 290 as a treatment for acute pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top